Recently, antibody mediated rejection (AMR) has been associated with a higher incidence of chronic lung allograft dysfunction (CLAD) and mortality after lung transplantation (LTx). We investigated markers related to AMR and matrix remodeling in CLAD, with special attention for its two phenotypes being bronchiolitis obliterans syndrome (BOS) and restrictive CLAD (rCLAD).status: publishe
Long-term survival after LTx is limited, mainly attributed to the development of chronic lung allogr...
Chronic lung allograft dysfunction (CLAD) remains the major barrier to long-term success after lung ...
Chronic lung allograft dysfunction (CLAD) is the main cause of poor survival and low quality of life...
Recently, antibody mediated rejection (AMR) has been associated with a higher incidence of chronic l...
Chronic rejection after organ transplantation is defined as a humoral- and cell-mediated immune resp...
Chronic rejection after organ transplantation is defined as a humoral- and cell-mediated immune resp...
International audienceA growing number of patients with end-stage lung disease have benefited from l...
BACKGROUND: Chronic lung allograft dysfunction (CLAD) remains a major risk factor for death after lu...
Chronic lung allograft dysfunction (CLAD) remains a major hurdle limiting long-term survival post lu...
RATIONALE: Patients can change chronic lung allograft dysfunction (CLAD) phenotype, especially from ...
In the past decade, considerable progress has been made in improving the outcome after lung transpla...
Chronic lung allograft dysfunction (CLAD) was recently introduced as an overarching term mainly to c...
Chronic lung allograft dysfunction (CLAD) remains a major problem after lung transplantation with no...
Understanding the distinct pathogenic mechanisms that culminate in allograft fibrosis and chronic gr...
Lung transplantation (LTx) is the final treatment option for patients suffering from end-stage lung ...
Long-term survival after LTx is limited, mainly attributed to the development of chronic lung allogr...
Chronic lung allograft dysfunction (CLAD) remains the major barrier to long-term success after lung ...
Chronic lung allograft dysfunction (CLAD) is the main cause of poor survival and low quality of life...
Recently, antibody mediated rejection (AMR) has been associated with a higher incidence of chronic l...
Chronic rejection after organ transplantation is defined as a humoral- and cell-mediated immune resp...
Chronic rejection after organ transplantation is defined as a humoral- and cell-mediated immune resp...
International audienceA growing number of patients with end-stage lung disease have benefited from l...
BACKGROUND: Chronic lung allograft dysfunction (CLAD) remains a major risk factor for death after lu...
Chronic lung allograft dysfunction (CLAD) remains a major hurdle limiting long-term survival post lu...
RATIONALE: Patients can change chronic lung allograft dysfunction (CLAD) phenotype, especially from ...
In the past decade, considerable progress has been made in improving the outcome after lung transpla...
Chronic lung allograft dysfunction (CLAD) was recently introduced as an overarching term mainly to c...
Chronic lung allograft dysfunction (CLAD) remains a major problem after lung transplantation with no...
Understanding the distinct pathogenic mechanisms that culminate in allograft fibrosis and chronic gr...
Lung transplantation (LTx) is the final treatment option for patients suffering from end-stage lung ...
Long-term survival after LTx is limited, mainly attributed to the development of chronic lung allogr...
Chronic lung allograft dysfunction (CLAD) remains the major barrier to long-term success after lung ...
Chronic lung allograft dysfunction (CLAD) is the main cause of poor survival and low quality of life...